HC Wainwright Reduces Earnings Estimates for Opus Genetics

Opus Genetics, Inc. (NASDAQ:IRD) – Stock analysts at HC Wainwright lowered their FY2025 earnings estimates for Opus Genetics in a research report issued on Tuesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($1.09) for the year, down from their previous forecast of ($1.03). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Opus Genetics’ FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.52) EPS and FY2028 earnings at ($0.22) EPS.

Separately, Jones Trading dropped their price objective on Opus Genetics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday.

Opus Genetics Trading Up 2.5 %

Shares of NASDAQ IRD opened at $0.93 on Thursday. The firm has a 50 day moving average price of $1.07. Opus Genetics has a 52-week low of $0.81 and a 52-week high of $1.56. The stock has a market capitalization of $29.89 million, a price-to-earnings ratio of -0.86 and a beta of 0.28.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings data on Monday, March 31st. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.93). The company had revenue of $3.40 million during the quarter, compared to analyst estimates of $11.10 million. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.